E Fund Management Co. Ltd. bought a new position in shares of Stryker Corporation (NYSE:SYK – Free Report) during the 2nd quarter, HoldingsChannel.com reports. The fund bought 2,247 shares of the medical technology company’s stock, valued at approximately $707,000.
A number of other hedge funds also recently bought and sold shares of the stock. Brighton Jones LLC boosted its position in shares of Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after purchasing an additional 609 shares during the period. Schnieders Capital Management LLC. purchased a new position in Stryker in the 2nd quarter valued at $205,000. Marshall Wace LLP boosted its holdings in shares of Stryker by 107.9% in the second quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock valued at $2,255,000 after acquiring an additional 77,831 shares in the last quarter. Nebula Research & Development LLC purchased a new stake in Stryker in the 2nd quarter valued at approximately $219,000. Finally, HUB Investment Partners LLC acquired a new position in Stryker during the second quarter worth $253,000. Institutional investors and hedge funds own 77.09% of the company’s stock.
Insider Activity
In related news, insider Debra King sold 826 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the sale, the insider owned 6,210 shares of the company’s stock, valued at $2,088,423. The trade was a 11.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. This represents a 30.04% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 315,370 shares of company stock worth $98,463,501 over the last three months. Corporate insiders own 4.60% of the company’s stock.
Stryker Stock Up 2.7%
Stryker (NYSE:SYK – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The firm had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm’s revenue was up 9.4% on a year-over-year basis. During the same period in the prior year, the business earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts anticipate that Stryker Corporation will post 15.02 EPS for the current year.
Stryker Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio is currently 36.48%.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on the company. Weiss Ratings restated a “hold (c)” rating on shares of Stryker in a report on Friday, July 31st. Canaccord Genuity Group decreased their price objective on Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a report on Friday, May 1st. UBS Group began coverage on shares of Stryker in a report on Tuesday, July 28th. They issued a “buy” rating and a $400.00 target price for the company. Royal Bank Of Canada dropped their price target on Stryker from $435.00 to $420.00 and set an “outperform” rating for the company in a research note on Friday, July 31st. Finally, Wolfe Research downgraded shares of Stryker from an “outperform” rating to a “peer perform” rating in a research note on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $386.28.
Stryker Company Profile
Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.
Featured Articles
- Five stocks we like better than Stryker
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
